Xenon (XENE) Receives a Buy from RBC Capital
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Brian Abrahams reiterated a Buy rating on Xenon Pharmaceuticals (XENE) with an $81.00 price target, following the stock's close at $64.55. The company holds a Strong Buy consensus with an average price target of $75.11, implying 16.36% upside. Additionally, TD Cowen maintained a Buy rating on XENE.
In a report released yesterday, Brian Abrahams from RBC Capital reiterated a Buy rating on Xenon, with a price target of $81.00. The company’s shares closed yesterday at $64.55.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine. According to TipRanks, Abrahams has an average return of 14.3% and a 56.11% success rate on recommended stocks.
Xenon has an analyst consensus of Strong Buy, with a price target consensus of $75.11, which is a 16.36% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.